SAFC Appointed By Affichem To Provide Chemical Development Services
Sigma-Aldrich is a leading Life Science and High Technology company. Its biochemical and organic chemical products and kits are used in scientific and genomic research, biotechnology, pharmaceutical development, the diagnosis of disease and as key components in pharmaceutical and other high technology manufacturing. The Company has customers in life science companies, university and government institutions, hospitals, and in industry.
St. Lous - SAFC, a member of the Sigma- Aldrich Group, announced that its SAFC Pharma business segment has been appointed by Affichem, a French biotechnology company, to provide chemical development services relating to Dendrogenine A, a potential cancer treatment.
Dendrogenine A, currently in pre-clinical development, is a new "first in class" molecule dedicated to the treatment of aggressive cancers. This compound contains an original mechanism of action, which makes tumor- producing, tumor-specific antigens and activates the cytotoxic T response against the tumor through the stimulation of the monocyte differentiation into "dendritic like" cells.
Chemists at the SAFC Manchester facility plan to conduct process research and development on the synthesis of the material to determine a suitable process for producing sufficient quantities of Dendrogenine A for future clinical trials and cGMP commercial production.
Stephane Silvente, Affichem CEO, said, "We are very pleased to be able to draw upon SAFC's chemical development expertise to assist us with this part of the Dendrogenine A development program."
SAFC President Frank Wicks adds, "Our chemical development partnership with Affichem to work on the Dendrogenine A program is one example of how SAFC's capabilities support the chemistry requirements of emerging and established pharmaceutical companies. SAFC's strategy combines experienced scientific talent with state-of-the-art technologies and facilities to offer customers a faster and more efficient method to obtain the high quality drug candidates they seek."
SAFC Pharma is focused on cGMP manufacturing, process development and contract services for small organic APIs and advanced intermediates, and the development of large molecule biopharmaceuticals.
SOURCE: SAFC